Successful Treatment of refractory Thrombotic Thrombocytopenic



























































































































 DEFGE I[	!  
		!" 


























































 '-K	 n [  , S
 "J
"' $ B9/%X< J +,g	 K	







BUN=91mg/dl  Cr=1.1mg/dl        ESR=25mm/1h 
Retic=1.2%  ASO=2+         CRP=2+    
RF=Neg   G6PD=Nor        LDH=3221u/l 
Hb=7.2g/dl   WBC=6.6×103  RBC=2.9×106/ml 




















































































































































































































































































































































































Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura with 
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Thrombotic thrombocytopenic purpura (TTP) is mostly attributed to the presence of an 
autoantibody against ADAMTS-13, a metalloprotease that degrades ultralarge von Willebrand 
protein multimers. Accumulation of vWF multimers and systemic platelet aggregation lead to 
microangiopathic thrombosis, hemolytic anemia, and end-organ ischemia. Most patients respond to 
therapeutic plasma exchange (TPE), which replaces the missing protease and removes the 
circulating inhibitor. However, some cases (10%-20%) might not respond to TPE alone, and, 
therefore, interest has been aroused to use the novel immunosuppressive anti-B-cell antibody, 
rituximab. We report a 12-year old male patient with severeTTP refractory to multiple courses of 
plasmapheresis and high-dose steroid treatment in whom the combined use of daily plasma 
exchange and rituximab was associated with clinical resolution of active TTP, and we discuss the 
benefits and possible timing of combined therapy. Retuximeb used with plasma exchange can lead 
to sustained clinical remission in patients with refractory autoimmune TTP. 
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